PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer

Protein Kinase D1 (PKD1) is a serine/threonine kinase encoded by the PRKD1 gene. PKD1 has been previously shown to be a prognostic factor in ERα+ tamoxifen-resistant breast tumors and PKD1 overexpression confers estrogen independence to ERα+ MCF7 cells. In the present study, our goal was to determine whether PKD1 is a prognostic factor and/or a relevant therapeutic target in breast cancer. We analyzed PRKD1 mRNA levels in 527 primary breast tumors. We found that high PRKD1 mRNA levels were significantly and independently associated with a low metastasis-free survival in the whole breast cancer population and in the triple-negative breast cancer (TNBC) subtype specifically. High PRKD1 mRNA levels were also associated with a low overall survival in TNBC. We identified novel PKD1 inhibitors and assessed their antitumor activity in vitro in TNBC cell lines and in vivo in a TNBC patient-derived xenograft (PDX) model. Pharmacological inhibition and siRNA-mediated depletion of PKD1 reduced colony formation in MDA-MB-436 TNBC cells. PKD1 inhibition also reduced tumor growth in vivo in a TNBC PDX model. Together, these results establish PKD1 as a poor prognostic factor and a potential therapeutic target in TNBC.

• Publication year

  2018

• Venue

  OncoTarget

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.25292PMID 29796183PMCID 5955414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1

  2017cited by this paper
• A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer

  2016cited by this paper
• Molecular aspects of breast cancer resistance to drugs (Review).

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101

  2015cited by this paper
• SD-208, a Novel Protein Kinase D Inhibitor, Blocks Prostate Cancer Cell Proliferation and Tumor Growth In Vivo by Inducing G2/M Cell Cycle Arrest

  2015cited by this paper
• Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands

  2014cited by this paper
• Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients

  2014cited by this paper
• Protein Kinase D1 Regulates Erα-positive Breast Cancer Cell Growth Response To 17β­estradiol And Contributes To Poor Prognosis In Patients

  2014cited by this paper
• Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis

  2013cited by this paper
• Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway.

  2012cited by this paper
• Molecular profiling of patient-derived breast cancer xenografts

  2012cited by this paper
• Regulation of Protein Kinase D1 Activity

  2012cited by this paper
• Proteinase-activated receptors 1 and 2 regulate invasive behavior of human melanoma cells via activation of protein kinase D1.

  2012cited by this paper
• Protein kinase D signaling: multiple biological functions in health and disease.

  2011cited by this paper
• Discovery of Diverse Small Molecule Chemotypes with Cell-Based PKD1 Inhibitory Activity

  2011cited by this paper
• Synthesis and Structure−Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D

  2011cited by this paper
• Targeted therapies for breast cancer.

  2011cited by this paper
• Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells

  2010cited by this paper
• A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo

  2010cited by this paper
• An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

  2010cited by this paper
• Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors.

  2010cited by this paper
• Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion

  2009cited by this paper
• Potent and Selective Disruption of Protein Kinase D Functionality by a Benzoxoloazepinolone*

  2008cited by this paper
• A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays

  2007cited by this paper
• Protein Kinase D Signaling*

  2005cited by this paper
• Quantification of estrogen receptor α and β expression in sporadic breast cancer

  2001cited by this paper
• Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.

  2001cited by this paper
• Inhibition of protein kinase D by resveratrol.

  2001cited by this paper
• Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.

  1999cited by this paper

• Triple Negative Breast Cancer Heterogeneity and Tumour Microenvironment- based Model Systems' Focus on Druggable Targets.

  2025cites this paper
• Effect of deletion of the protein kinase PRKD1 on development of the mouse embryonic heart

  2024cites this paper
• Protein kinase D1 overexpression potentiates epidermal growth factor signaling pathway in MCF-7 cells

  2023cites this paper
• Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology

  2023cites this paper
• Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity

  2022cites this paper
• Value of serum p53, PKD1, and MAP2K4 in evaluating the condition and prognosis of endometrial carcinoma.

  2022cites this paper
• Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop

  2022cites this paper
• Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.

  2022cites this paper
• Multiplexed and reproducible high content screening of live and fixed cells using the Dye Drop method

  2021cites this paper
• Protein Kinase D1 Is Increased in Tumor Tissue, Correlates With Advanced Tumor Features and Worse Prognosis of Non-Small Cell Lung Cancer

  2020influential citation
• Protein Kinase D1 (PKD1) Is a New Functional Non-Genomic Target of Bisphenol A in Breast Cancer Cells

  2020cites this paper
• Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.

  2020cites this paper
• Homeobox transcription factor engrailed homeobox 1 is a possible diagnostic marker for adenoid cystic carcinoma and polymorphous adenocarcinoma

  2020cites this paper
• Hypermethylation of RAD9A intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformation

  2020cites this paper
• microRNA: The Impact on Cancer Stemness and Therapeutic Resistance

  2019cites this paper
• Twist1-induced epithelial dissemination requires Prkd1 signaling.

  2019cites this paper